Save

Effects of Intragastric Quinine, Alone or Combined With L-leucine, on Postprandial Glycaemic Control

RECRUITING

In this study, participants will receive, in a randomized, double-blind fashion, an intragastric bolus administration of either (i) 300 mg quinine, (ii) 5 g L-leucine, (iii) a combination of (i)+(ii), or (iv) control, before 350 ml (500 kcal) of a mixed-nutrient drink, to evaluate the effects on postprandial blood glucose, gastric emptying, and the hormone responses to the mixed-nutrient drink. Study visits will be separated by 3-7 days and participants will receive one treatment per visit. On each study visit, the participant will be intubated with a nasogastric feeding tube.

At t= - 60 min (08:30 am), a baseline blood sample, visual analogue scale questionnaire (VAS), and breath sample will be collected and quinine or control will be administered through the feeding tube. 30 min later (at t= - 30 min), L-leucine or control will be administered over 2 min after which the feeding tube will be removed immediately. At t = -45, -30, -15, and -1 min further blood samples will be collected and VAS completed.

At t = -1 min, participants will consume, within 1 minute, a mixed-nutrient drink, labelled with 100 mg of 1-13C-acetate for measurement of gastric emptying by breath sampling. Blood samples, VAS, and breath samples will be taken at regular intervals between t = 0-180 min.

Simpliy with AI

Study details:

This trial aims to assess the effects of intragastric administration of quinine, combined with L-leucine, on postprandial blood glucose, gastric emptying, gut and gluco-regulatory hormones, as well as GI symptoms in response to a mixed-nutrient drink. Each participant will be studied on 4 occasions, separated by 3-7 days. Participants will receive, in randomized, double-blind fashion, an intragastric bolus of (i) 300 mg quinine, (ii) 5 g L-leucine, (iii) combination of (i)+(ii), or (iv) control.

Due to the low water solubility, L- leucine will be provided as a suspension using 5 ml of 'the suspending agent' Ora-Plus (manufactured by Perrigo, Minneapolis). Visits will be carried out at the Clinical Research Facility, Adelaide Medical School, University of Adelaide, by staff and students trained in the required clinical research techniques. Participants will consume a standardized dinner meal (400g McCain's beef lasagne) the night before each study visit by no later than 7 pm.

After fasting for 13. 5 hours overnight and refraining from alcohol and exercise for 24 hours, participants will arrive at the Clinical Research Facility by 8:30 am. Upon arrival, participants will be intubated with a nasogastric, custom-built soft silicon feeding tube (outer diameter: 4mm; Dentsleeve, Mississauga, Ontario, Canada) that will be inserted through an anaesthetized nostril and placed in the stomach.

An intravenous cannula will be placed into a right forearm vein for regular blood sampling. At t = -60 min, a venous baseline blood sample (6 ml) will be collected and the participant will complete a visual analogue scale questionnaire (VAS) to assess GI symptoms (nausea and bloating). Immediately thereafter, the participant will receive a 10- ml intragastric bolus of either 300 mg quinine-hydrochloride (Q-HCl) or water (control), and 30 min later, at t -30 min, an intragastric bolus of L-leucine (100 ml suspension consisting of 5 g L- leucine, 5 ml Ora-Plus and 90 ml 0.

9% saline) or control (5 ml Ora-Plus and 95 ml saline) over 1 min after which time the catheter will be removed immediately. At t = -1 min, the participant will consume, within 1 min, a mixed-nutrient drink (Nestle, 500 kcal, 350 ml, 56 g carbohydrates) labelled with 100 mg of 1-13C-acetate for measurement of gastric emptying by breath sampling. Breath samples will be collected in sealed breath bags at baseline (prior to quinine administration) and at regular intervals between t = 0-180 min, for subsequent analysis of 13CO2 concentration in exhaled breath.

Blood samples for the measurement of glucose and plasma concentrations of hormones will be taken regularly (12 sampling time points in total), and participant complete VAS questionnaires. At t = 180 min, after final blood and breath samples and VAS measurements, the intravenous cannula will be removed and the participant will be served a light lunch, after which they will be allowed to leave the laboratory.

Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

Lean weight (BMI 19-25 kg/m2)

Exclusion criteria

Significant gastrointestinal symptoms, disease or surgery;

Current gallbladder or pancreatic disease;

Cardiovascular or respiratory diseases;

Any other illnesses as assessed by the investigator (including chronic illnesses not explicitly listed above);

Use of prescribed or non-prescribed medications (including vitamins and herbal supplements) which may affect energy metabolism, gastrointestinal function, bodyweight or appetite (eg domperidone and cisapride, anticholinergic drugs (eg atropine), metoclopramide, erythromycin, hyoscine, orlistat, green tea extracts, Astragalus, St Johns Wort etc.);

Individuals with low ferritin levels (less than 30 ng/mL), or who have donated blood in the 12 weeks prior to taking part in the study;

Lactose intolerance/other food allergy(ies);

Vegetarians;

Restrained eaters (score >12 on the three-factor eating questionnaire);

Current intake of greater than 2 standard drinks on greater than 5 days per week;

Current smokers of cigarettes/cigars/marijuana;

Current intake of any illicit substance;

High performance athletes;

Inability to comprehend study protocol;

Unable to tolerate naso-gastric tube

Simplify with AI

Eligibility

Age eligible for study : 18 and older

Healthy volunteers accepted : Yes

Gender eligible for study: Male

Things to know

Study dates

Study start: 2023-02-02

Primary completion: 2024-08-01

Study completion finish: 2024-08-01

Study type

OTHER

Phase

Trial ID

NCT05720390

Intervention or treatment

OTHER: Quinine

OTHER: L-leucine

OTHER: Combination of quinine and L-leucine

OTHER: Control

Conditions

• Healthy

Condition: Healthy
OTHER: Quinine and other drugs
Adelaide, South Australia, Australia
Sponsor: University of Adelaide

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial? If you're a clinic or sponsor, you can claim this study. Claim or learn more.

Find a site

Closest Location:

Clinical Research Facility, Adelaide Health and Medical Sciences Building

Research sites nearby

Select from list below to view details:

Clinical Research Facility, Adelaide Health and Medical Sciences Building
Adelaide, South Australia, Australia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/Arm	Intervention/Treatment
ACTIVE_COMPARATOR: Quinine only In this arm, participants will receive a 10 ml intragastric bolus of 300 mg quinine followed 30 min later by 100 ml intragastric bolus of control for L-leucine.	OTHER: Quinine Quinine, which is a bitter compound, extracted from the bark of the cinchona tree and has been shown in our previous studies to lower blood glucose in doses of 300-600 mg, will be 'active' in this condition.
ACTIVE_COMPARATOR: L-leucine only In this arm, participants will receive a 10 ml intragastric bolus of control for quinine followed 30 min later by 100 ml intragastric bolus of 5 g L-leucine.	OTHER: L-leucine L-leucine, which is a branched-chain amino acid, and one of the building blocks of protein, therefore is part of our daily diet, will be 'active' in this condition.
ACTIVE_COMPARATOR: Quinine + L-leucine In this arm participants will receive a 10 ml intragastric bolus of 300 mg quinine followed 30 min later by 100 ml intragastric bolus of 5 g L-leucine.	OTHER: Combination of quinine and L-leucine In this condition, both quinine and L-leucine will be administered as 'active'.
PLACEBO_COMPARATOR: Control In this arm, participants will receive a 10 ml intragastric bolus of control solution followed 30 min later by 100 ml intragastric bolus of control solution.	OTHER: Control In the condition, where quinine is 'active', control for L-leucine (5 ml oraplus and 95 ml saline) will be administered. In the condition, where L-leucine will be 'active', control for quinine (10 ml distilled water) will be administered.

What is the study measuring?

Primary outcome

Primary Outcome Measure	Primary Outcome Description	Primary Outcome Time Frame
Change from baseline plasma glucose concentration after a mixed-nutrient drink for 3 hours	Plasma glucose concentrations (mmol/L) will be assessed using glucose oxidase method	Blood samples will be taken repeatedly within each study visit (i.e. at baseline (t= 0 minute), after administration of study treatments (t= -45, -30, -15 minutes) and after a mixed-nutrient drink (t= 0, 15, 30, 45, 60, 90, 120 and 180 minutes).

Secondary outcome

Secondary Outcome Measure	Secondary Outcome Description	Secondary Outcome Time Frame
Gastric emptying of a mixed nutrient drink	Measurement of 13CO2 in breath samples, expressed as percentage of 13CO2 recovery per hour	Breath samples will be taken repeatedly on each study visit (i.e. t= 0 (baseline), 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 75, 90, 105,120, 135, 150, 165, 180 minutes) to construct a gastric emptying profile on each day.
Plasma concentration of insulin after a mixed-nutrient drink	Plasma insulin concentrations (mU/L) will be assessed using an ELISA immunoassay.	Blood samples will be taken repeatedly within each study visit (i.e. at baseline (t= 0 minute), after administration of study treatments (t= -45, -30, -15 minutes) and after a mixed-nutrient drink (t= 0, 15, 30, 45, 60, 90, 120 and 180 minutes).
Plasma concentration of glucagon after a mixed-nutrient drink	Plasma glucagon concentrations (pg/mL) will be measured by radioimmunoassay	Blood samples will be taken repeatedly within each study visit (i.e. at baseline (t= 0 minute), after administration of study treatments (t= -45, -30, -15 minutes) and after a mixed-nutrient drink (t= 0, 15, 30, 45, 60, 90, 120 and 180 minutes).
Plasma concentration of glucagon-like peptide-1 (GLP-1) after a mixed-nutrient drink	Plasma total GLP-1 concentrations (pmol/L) will be measured using a radioimmunoassay	Blood samples will be taken repeatedly within each study visit (i.e. at baseline (t= 0 minute), after administration of study treatments (t= -45, -30, -15 minute) and after a mixed-nutrient drink (t= 0, 15, 30, 45, 60, 90, 120 and 180 minutes).
Gastrointestinal symptoms (nausea and bloating)	Gastrointestinal symptoms will be measured using a 100-mm Visual Analogue Scale (VAS) questionnaire. The minimum value means no feeling at all, and the highest value means feeling very much.	Visual Analogue ratings will be collected repeatedly within each study visit (i.e. at baseline (t = 0 minute), after administration of treatments (t= -45, -30, -15 minutes) and after mixed-nutrient drink (t= 0, 15, 30, 45, 60, 90, 120 and 180 minutes).

Frequently Asked Questions

Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

No questions submitted. Be the first to ask a question!

You may be eligible to participate in this trial based on your search.Apply for study

Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

References

Clinical Trials Gov: Effects of Intragastric Quinine, Alone or Combined With L-leucine, on Postprandial Glycaemic Control